Physician profile
Michael C Pinell
NPI 1841267606
$1,039.99
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $182 · 2022: $23.85 · 2023: $79.28 · 2024: $17.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.85 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.85 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $201.04 | 2019-2020 | |
| Tesaro, INC. | $113.40 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $92.07 | 2019-2024 | Fasenra |
| Celgene Corporation | $82.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.68 | 2019-2020 | |
| Amgen INC. | $72.34 | 2019 | |
| Csl Behring | $68.34 | 2022-2023 | Kcentra |
| Pharmacyclics LLC, An Abbvie Company | $64.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.91 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.82 | 2020-2023 | Eliquis |
| Melinta Therapeutics, LLC | $31.58 | 2019 | |
| Lilly USA, LLC | $30.31 | 2019-2020 | |
| Kyowa Kirin, INC. | $28.71 | 2019 | |
| Gilead Sciences, INC. | $17.54 | 2023 | Veklury |
| Seagen INC. | $15.58 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $15.58 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.54 | 2019 | |
| Clovis Oncology, INC. | $11.60 | 2020 | |
| Incyte Corporation | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pinell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.